Shots:

• The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg- q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5yrs.
• Results: 87.4% mean reduction in attack rate compared to baseline; attacks requiring acute treatment (93.4%); mod. or sev. attacks (84.3%); HAE attack-free (97.7%) with a duration of the attack-free period (14.8mos.)- 68.9% experienced an attack-free period of 12+ mos.
• Additionally- the safety profile was consistent with the original findings from the HELP Study with TEAEs occurring in 54.7% of patients. Takhzyro is a mAb targeting plasma kallikrein activity- indicated for HAE attacks in patients aged ≥12 yrs.

| Ref: Takeda | Image: The Japan Times